DOCSLIB.ORG

Icrs2015 Programme

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Icrs2015 Programme TH 25 ANNUAL SYMPOSIUM OF THE INTERNATIONAL CANNABINOID RESEARCH SOCIETY WOLFVILLE NOVA SCOTIA JUNE 28 - JULY 3, 2015 TH 25 ANNUAL SYMPOSIUM OF THE INTERNATIONAL CANNABINOID RESEARCH SOCIETY WOLFVILLE JUNE 28 – JULY 3, 2015 Symposium Programming by Cortical Systematics LLC Copyright © 2015 International Cannabinoid Research Society Research Triangle Park, NC USA ISBN: 978-0-9892885-2-1 These abstracts may be cited in the scientific literature as follows: Author(s), Abstract Title (2015) 25th Annual Symposium on the Cannabinoids, International Cannabinoid Research Society, Research Triangle Park, NC, USA, Page #. Funding for this conference was made possible in part by grant 5R13DA016280-13 from the National Institute on Drug Abuse. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government. Sponsors ICRS Government Sponsors National Institute on Drug Abuse Non- Profit Organization Sponsors Kang Tsou Memorial Fund 2015 ICRS Board of Directors Executive Director Cecilia Hillard, Ph.D. President Stephen Alexander, Ph.D. President- Elect Michelle Glass, Ph.D. Past President Ethan Russo, M.D. Secretary Steve Kinsey, Ph.D. Treasurer Mary Abood, Ph.D. International Secretary Roger Pertwee, D . Phil. , D . S c. Student Representative Tiffany Lee, Ph.D. Grant PI Jenny Wiley, Ph.D. Managing Director Jason Schechter, Ph.D. 2015 Symposium on the Cannabinoids Conference Coordinators Steve Alexander, Ph.D. Cecilia Hillard, Ph.D. Mary Lynch, M.D. Jason Schechter, Ph.D. Sara Whynot Myrna Yazer Programme Committee Mary Abood, Ph.D. Steve Alexander, Ph.D. Heather B Bradshaw, Ph.D. Michelle Glass, Ph.D. Matthew Hill, Ph.D Melanie Kelly, Ph.D. Steve Kinsey, Ph.D., Mary Lynch, M.D. Mauro Maccarrone, Ph.D. Sachin Patel, M.D., Ph.D. Roger Pertwee, D.Phil., D.Sc. Ethan Russo, M.D. Kasia Starowicz, Ph.D. Jenny Wiley, Ph.D. Committee on Awards Steve Kinsey, Ph.D., Chair Sachin Patel, M.D., Ph.D. Student Award Committee Chairs Eliot Gardner, Ph.D. Melanie Kelly, Ph.D. Mechoulam Award Committee Francis Barth, Ph.D. Benjamin Cravatt, Ph.D. Vincenzo Di Marzo, Ph.D. Cecilia Hillard, Ph.D. Allyn Howlett, Ph.D. John Huffman, Ph.D. George Kunos, M.D., Ph.D. Gerard Le Fur, Ph.D. Aron Lichtman, Ph.D. Beat Lutz, Ph.D. Ken Mackie, M.D. Alex Makriyannis, Ph.D. Roger Pertwee, D.Phil., D.Sc. Raj Razdan, Ph.D. Patti Reggio, Ph.D. Murielle Rinaldi- Carmona, Ph.D th Registration: June 28 , 2015, 16.00 – 18.00 Festival Theatre - Lobby Welcome Reception: 18.30 – 20.00 KC Irving Centre Day 1 Monday, June 29th 7.30 Breakfast Welcome and Opening Remarks 8.30 Festival Theatre Oral Session 1. Novel chemical entities MODERATORS: ROGER PERTWEE, D.PHIL, D.SC. AND YOSSI TAM, D.M.D, PH.D. Resat Cinar, Malliga Iyer, Ziyi Liu, Tony PERIPHERALLY RESTRICTED, DUAL Jourdan, Katalin Erdelyi, TARGET CB1R ANTAGONISTS WITH 9.00 Grzegorz Godlewski, 1 IMPROVED SAFETY AND ANTI- Gergo Szanda, Jie Liu, FIBROTIC EFFICACY Pal Pacher, Kenner Rice and George Kunos Brian F. Thomas, Gregory W. Endres, Jenny L. Wiley, Gerald CHEMICAL EXPOSURES AND RISKS T. Pollard, Ann M. ASSOCIATED WITH VAPORIZATION 9.15 2 Decker, Elaine A. Gay, AND INHALATION OF SYNTHETIC Purvi R. Patel, Alexander CANNABINOIDS L. Kovach and Megan Grabenauer Jenny L. Wiley, HIGH EFFICACY DEGRADANTS OF Brian F. Thomas, SYNTHETIC CANNABINOIDS EXHIBIT 9.30 Julie A. Marusich, 3 POTENT SUBSTITUTION IN JWH-018 Timothy W. Lefever DISCRIMINATION IN MICE and Gregory W. Endres Spyros P. Nikas, Shashank Kulkarni, Rishi Sharma, Carol A. Paronis, Shan Jiang, Jimit Girish Raghav, SAFER EFFECTIVE CANNABINOIDS 9.45 Chandrashekhar Honrao, THROUGH CONTROLLED 4 Srikrishnan Mallipeddi, DEACTIVATION Roger S. Gifford, Torbjörn U.C. Järbe, Jack Bergman and Alexandros Makriyannis CANNABIS-DERIVED COMPOUNDS AS CANNABINOID RECEPTOR Pankaj Pandey, MODULATORS: SYSTEMATIC 10.00 Kuldeep K. Roy 5 ANALYSIS USING MOLECULAR and Robert J. Doerksen DOCKING AND BINDING FREE-ENERGY STUDIES Dai Lu, Hamed I. Ali, DESIGN AND SYNTHESIS OF Changjiang Qiao, PHOTOACTIVATABLE AFFINITY 10.15 Kwang H. Ahn, 6 LIGANDS FOR THE CB1 ALLOSTERIC Leepakshi Khurana SITE and Debra A. Kendall 10.30 Break Oral Session 2. Plant Studies and Non-THC Cannabinoids MODERATORS: ETHAN RUSSO, M.D. AND RANGAN (RONNIE) MAITRA, PH.D. Kazuhito Watanabe, Satoshi Yamaori, Rongrong Jiang, INDUCIBILITY OF CYP ENZYMES 11.00 7 Yuka Kinugasa, BY CANNABIDIOL Yoshimi Okushima and Ikuo Yamamoto Justine Renard, CANNABIDIOL’S ANTIPSYCHOTIC Michael Loureiro, PROPERTIES IN THE MESOLIMBIC 11.15 Laura G. Rosen, 8 PATHWAY: ROLE OF MTORC/P70S6K Walter J. Rushlow SIGNALLING and Steven R. Laviolette CANNABIDIOL REDUCES THE Blathnaid Hughes ATTENUATION OF HIPPOCAMPAL 11.30 9 and Caroline E. Herron LONG-TERM POTENTIATION IN MODELS OF ALZHEIMER’S DISEASE Daniel I Brierley, CANNABIGEROL ATTENUATES Joe R Harman, Natasa MUSCLE CATABOLISM AND Giallourou, Jonathan R 11.45 ANOREXIA IN A PRE-CLINICAL 10 Swann, Ketan Patel, MODEL OF CHEMOTHERAPY- Benjamin J Whalley INDUCED CACHEXIA and Claire M Williams Jahan P. Marcu, IMPROVING QUALITY CONTROL James Neal-Kababick, 12.00 METHODS FOR CANNABIS USING 11 Melissa Wilcox FLASH CHROMATOGRAPHY and Mark Jacyno THE SEED PROJECT: DEVELOPMENT N. Rielle Capler, Kim OF STANDARDS AND CERTIFICATION 12.15 Crosby, Philippe Lucas 12 PROGRAM FOR MEDICAL CANNABIS and Zachary Walsh DISPENSARIES IN CANADA Kevin McKernan, SEQUENCING OF THREE MALE Vasisht Tadigotla, CANNABIS GENOMES AND 12.30 Yvonne Helbert, Jessica DEVELOPMENT OF MULTIPLEX 13 Spangler, Lei Zhang QPCR ASSAYS FOR RAPID MALE and Douglas Smith SEX DETERMINATION Kevin McKernan, Cameron Miller, Brad Douglass, Jessica GENOMIC, TERPENE Spangler, Braden Doane, AND CANNABINOID PROFILES 12.45 Vasisht Tadigotla, Colin 14 OF A PUTATIVELY Montgomery, Yvonne NOVEL CANNABIS SPECIES Helbert, Lei Zhang, Douglas Smith and Jeffrey Raber LUNCH 13.00 NIDA Lunch & Mentoring Wheelock Dining Hall Poster Session P1 14.00 - 16.00 Fountain Commons ODD Presidential Plenary Speaker FROM RECEPTORS TO PAIN: 16.00 THE MOLECULAR DYNAMICS OF PAIN Michael Salter, M.D., Ph.D. Hospital for Sick Children and University of Toronto Toronto, Canada 17.00 Break Oral Session 3. Animal Models MODERATORS: JENNY WILEY, PH.D. AND JAMES BURSTON, PH.D. Shiran Udi, Liad Hinden, ROLE OF PROXIMAL TUBULAR Adi Drori, Rivka Hadar, CANNABINOID-1 RECEPTOR IN 17.30 Brian Earley, 15 OBESITY-INDUCED RENAL Resat Cinar, Ken Mackie DYSFUNCTION and Joseph Tam SEXUALLY DIMORPHIC EFFECTS Angela M. Williams, OF ALCOHOL WITHDRAWAL ON 17.45 Anthony L. Berger ENDOCANNABINOID GENE 16 and Ryan J. McLaughlin EXPRESSION AND ANXIETY-LIKE BEHAVIOR Sara Peñasco, Nagore Puente, Almudena Ramos, Naiara Royo, Ana Gutiérrez, Itziar ALTERATION OF THE Bonilla, Leire Reguero, ENDOCANNABINOID-DEPENDENT Miren-Josune Canduela, 18.00 SYNAPTIC PLASTICITY IN ADULT 17 Juan Mendizabal- BRAIN AFTER ETHANOL EXPOSURE Zubiaga, Fernando OF MICE DURING ADOLESCENCE Rodríguez de Fonseca, Juan Suárez, Izaskun Elezgarai and Pedro Grandes Zheng-Xiong Xi, Hai- COCAINE SELF-ADMINISTRATION Ying Zhang, Qing-Rong 18.15 UP-REGULATES CANNABINOID CB2 18 Liu, Guo-Hua Bi GENE EXPRESSION IN MOUSE BRAIN and Eliot L. Gardner Jayme R McReynolds, GLUCOCORTIOID- Elizabeth M Doncheck, ENDOCANNABINOID INTERACTIONS Oliver Vranjkovic, Evan IN THE PRELIMBIC CORTEX 18.30 19 N Graf, Qing-song Liu, MEDIATE STRESS-POTENTIATED Cecilia J Hillard REINSTATEMENT OF and John R Mantsch COCAINE SEEKING EFFECT OF CHRONIC CANNABINOID Sara Jane Ward, AGONIST TREATMENT ALONE OR IN 18.45 Patrick Siegele COMBINATION WITH CANNABIDIOL 20 and Ronald Tuma ON WITHDRAWAL BEHAVIORS IN MICE Martin A. Sticht, Cheryl L. Limebeer, Rehab A. Abdullah, 2-ARACHIDONOYLGLYCEROL Justin L. Poklis, Winnie MEDIATES THE ANTI-NAUSEA 19.00 Ho, Micah J. Niphakis, EFFECTS OF THE VISCERAL INSULAR 21 Keith A. Sharkey, CORTEX ENDOCANNABINOID Benjamin F. Cravatt, SYSTEM IN RATS Aron H. Lichtman and Linda A. Parker Carol A. Paronis, Girish R. Chopda, SPONTANEOUS CANNABINOID 19.15 Spyros P. Nikas, WITHDRAWAL IN MICE: EVIDENCE 22 Vidyanand G. Shukla FROM THREE BEHAVIORAL ASSAYS and Alex Makriyannis Dinner 19.30 Wheelock Dining Hall Day 2 Tuesday, June 30th 7.30 Breakfast Oral Session 4. CB2 Receptors MODERATORS: ANDREA HOHMANN, PH.D. AND JAYME MCREYNOLDS, PH.D. Tomohiro Kimura, Krishna Vukoti, Diane L. GLOBAL FOLD OF HUMAN Lynch, Dow P. Hurst, CANNABINOID TYPE 2 RECEPTOR 8.30 Alan Grossfield, Michael PROBED BY SOLID-STATE NMR 23 C. Pitman, Patricia H. AND MOLECULAR DYNAMICS Reggio, Alexei Yeliseev SIMULATIONS and Klaus Gawrisch Uwe Grether, Jean-Michel Adam, Christian M. Apfel, Stefanie Bendels, Caterina Bissantz, Jürgen Fingerle, Ivan Formentini, Jürgen Funk, 2,4,5-TRISUBSTITUTED PYRIDINES – Sabine Grüner, A NOVEL CLASS OF HIGHLY POTENT, 8.45 Atsushi Kimbara, 24 HIGHLY SELECTIVE AND IN VIVO Matthias Nettekoven, ACTIVE CB2 AGONISTS Giorgio Ottaviani, Camille Perret, Mark Rogers-Evans, Benno Rothenhäusler, Stephan Röver, Franz Schuler, Tanja Schulz-Gasch and Christoph Ullmer Natalia Malek, Magdalena Kostrzewa, TARGETING PERIPHERAL Michal Korostynski, CANNABINOID RECEPTORS CB2 9.00 Julia Borowczyk, 25 AS A NOVEL THERAPY TO TREAT Zbigniew Madeja, OSTEOARTHRITIS Justyna Drukala and Katarzyna Starowicz Dan Ting Kho, DO CIRCULATING MONOCYTES Kristina Burkert, IN HUMANS REPRESENT A 9.15 Michelle Glass, THERAPEUTIC TARGET FOR CB2- 26 Kate Angel MIMETIC DRUGS OR IS IT THEIR
Load more

Recommended publications
  • Cannabidiol Attenuates Seizures and Social Deficits in a Mouse Model of Dravet Syndrome
    Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome Joshua S. Kaplana, Nephi Stellaa,b,1, William A. Catteralla,1,2, and Ruth E. Westenbroeka,1 aDepartment of Pharmacology, University of Washington, Seattle, WA 98195; and bDepartment of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA 98195 Contributed by William A. Catterall, September 7, 2017 (sent for review July 3, 2017; reviewed by Lori L. Isom, Daniele Piomelli, and Peter C. Ruben) Worldwide medicinal use of cannabis is rapidly escalating, despite 17). Previous work showed that DS symptoms result from the loss- limited evidence of its efficacy from preclinical and clinical studies. of-function of Nav1.1 channels, which selectively reduces sodium Here we show that cannabidiol (CBD) effectively reduced seizures current and excitatory drive in many types of GABAergic inter- and autistic-like social deficits in a well-validated mouse genetic neurons (13, 14, 18–20). Accordingly, targeting the Scn1a mutation model of Dravet syndrome (DS), a severe childhood epilepsy disorder to Nav1.1 channels in forebrain GABAergic interneurons re- caused by loss-of-function mutations in the brain voltage-gated capitulated the DS phenotype and established that hypoexcitability sodium channel NaV1.1. The duration and severity of thermally in- of these interneurons is sufficient to cause the epileptic phenotype duced seizures and the frequency of spontaneous seizures were sub- (21) and autistic-like behaviors (16) observed in DS mice. In con- stantially decreased. Treatment with lower doses of CBD also trast, targeting the Scn1a mutation to excitatory neurons ameliorates improved autistic-like social interaction deficits in DS mice.
    [Show full text]
  • Analysis of Drugs Manual September 2019
    Drug Enforcement Administration Office of Forensic Sciences Analysis of Drugs Manual September 2019 Date Posted: 10/23/2019 Analysis of Drugs Manual Revision: 4 Issue Date: September 5, 2019 Effective Date: September 9, 2019 Approved By: Nelson A. Santos Table of Contents CHAPTER 1 – QUALITY ASSURANCE ......................................................................... 3 CHAPTER 2 – EVIDENCE ANALYSIS ......................................................................... 93 CHAPTER 3 – FIELD ASSISTANCE .......................................................................... 165 CHAPTER 4 – FINGERPRINT AND SPECIAL PROGRAMS ..................................... 179 Appendix 1A – Definitions ........................................................................................... 202 Appendix 1B – Acronyms and Abbreviations .............................................................. 211 Appendix 1C – Instrument Maintenance Schedule ..................................................... 218 Appendix 1D – Color Test Reagent Preparation and Procedures ............................... 224 Appendix 1E – Crystal and Precipitate Test Reagent Preparation and Procedures .... 241 Appendix 1F – Thin Layer Chromatography................................................................ 250 Appendix 1G – Qualitative Method Modifications ........................................................ 254 Appendix 1H – Analytical Supplies and Services ........................................................ 256 Appendix 2A – Random Sampling Procedures
    [Show full text]
  • Cannabinoids and Endocannabinoid System Changes in Intestinal Inflammation and Colorectal Cancer
    cancers Review Cannabinoids and Endocannabinoid System Changes in Intestinal Inflammation and Colorectal Cancer Viktoriia Cherkasova, Olga Kovalchuk * and Igor Kovalchuk * Department of Biological Sciences, University of Lethbridge, Lethbridge, AB T1K 7X8, Canada; [email protected] * Correspondence: [email protected] (O.K.); [email protected] (I.K.) Simple Summary: In recent years, multiple preclinical studies have shown that changes in endo- cannabinoid system signaling may have various effects on intestinal inflammation and colorectal cancer. However, not all tumors can respond to cannabinoid therapy in the same manner. Given that colorectal cancer is a heterogeneous disease with different genomic landscapes, experiments with cannabinoids should involve different molecular subtypes, emerging mutations, and various stages of the disease. We hope that this review can help researchers form a comprehensive understanding of cannabinoid interactions in colorectal cancer and intestinal bowel diseases. We believe that selecting a particular experimental model based on the disease’s genetic landscape is a crucial step in the drug discovery, which eventually may tremendously benefit patient’s treatment outcomes and bring us one step closer to individualized medicine. Abstract: Despite the multiple preventive measures and treatment options, colorectal cancer holds a significant place in the world’s disease and mortality rates. The development of novel therapy is in Citation: Cherkasova, V.; Kovalchuk, critical need, and based on recent experimental data, cannabinoids could become excellent candidates. O.; Kovalchuk, I. Cannabinoids and This review covered known experimental studies regarding the effects of cannabinoids on intestinal Endocannabinoid System Changes in inflammation and colorectal cancer. In our opinion, because colorectal cancer is a heterogeneous Intestinal Inflammation and disease with different genomic landscapes, the choice of cannabinoids for tumor prevention and Colorectal Cancer.
    [Show full text]
  • Cannabinoid-Induced Hypotension and Bradycardia in Rats Is 1 Mediated by CB1-Like Cannabinoid Receptors
    0022-3565/97/2813-1030$03.00/0 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 281, No. 3 Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. JPET 281:1030–1037, 1997 Cannabinoid-Induced Hypotension and Bradycardia in Rats Is 1 Mediated by CB1-Like Cannabinoid Receptors KRISTY D. LAKE, DAVID R. COMPTON, KAROLY VARGA, BILLY R. MARTIN and GEORGE KUNOS Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia Accepted for publication February 19, 1997 ABSTRACT 9 Previous studies indicate that the CB1 cannabinoid receptor an- potency was (-)-11-OH-D -THC dimethylheptyl $ (-)-3-[2- tagonist, N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophe- hydroxy-4-(1,1-dimethyl-heptyl)phenyl]-4-[3-hydroxy-propyl]cy- nyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A), in- clohexan-1-ol . (-)-3-[2-hydroxy-4-(1,1-dimethyl-heptyl)phenyl]- hibits the anandamide- and D9-tetrahydrocannabinol- (THC) 4-[3-hydroxy-propyl]cyclohexan-1-ol . THC . anandamide $ induced hypotension and bradycardia in anesthetized rats with a (-)-3-[2-hydroxy-4-(1,1-dimethyl-heptyl)phenyl]-4-[3-hydroxy- potency similar to that observed for SR141716A antagonism of propyl]cyclohexan-1-ol, which correlated well with CB1 receptor THC-induced neurobehavioral effects. To further test the role of affinity or analgesic potency (r 5 0.96-0.99). There was no hypo- CB1 receptors in the cardiovascular effects of cannabinoids, we tension or bradycardia after palmitoylethanolamine or (1)-11-OH- examined two additional criteria for receptor-specific interactions: D9-THC dimethylheptyl.
    [Show full text]
  • Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma
    cells Article Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma Tamara T. Lah 1,2,3,*, Metka Novak 1, Milagros A. Pena Almidon 4, Oliviero Marinelli 4 , Barbara Žvar Baškoviˇc 1, Bernarda Majc 1,3, Mateja Mlinar 1, Roman Bošnjak 5, Barbara Breznik 1 , Roby Zomer 6 and Massimo Nabissi 4 1 Department of Genetic Toxicology and Cancer Biology, National Institute of Biology, 1000 Ljubljana, Slovenia; [email protected] (M.N.); [email protected] (B.Ž.B.); [email protected] (B.M.); [email protected] (M.M.); [email protected] (B.B.) 2 Faculty of Chemistry and Chemical Technology, University of Ljubljana, 1000 Ljubljana, Slovenia 3 Jožef Stefan International Postgraduate School, 1000 Ljubljana, Slovenia 4 School of Pharmacy, Experimental Medicine Section, University of Camerino, 62032 Camerino, Italy; [email protected] (M.A.P.A.); [email protected] (O.M.); [email protected] (M.N.) 5 Department of Neurosurgery, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia; [email protected] 6 MGC Pharmaceuticals d.o.o., 1000 Ljubljana, Slovenia; [email protected] * Correspondence: [email protected]; Tel.: +386-41-651-629 Simple Summary: Among primary brain tumours, glioblastoma is the most aggressive. As early relapses are unavoidable despite standard-of-care treatment, the cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) alone or in combination have been suggested as a combined treatment strategy for glioblastomas. However, the known psychoactive effects of THC hamper its medical applications in these patients with potential cognitive impairment due to the progression of the Citation: Lah, T.T.; Novak, M.; Pena Almidon, M.A.; Marinelli, O.; disease.
    [Show full text]
  • Screening of Bacterial Quorum Sensing Inhibitors in a Vibrio fischeri Luxr-Based Synthetic Fluorescent E
    pharmaceuticals Article Screening of Bacterial Quorum Sensing Inhibitors in a Vibrio fischeri LuxR-Based Synthetic Fluorescent E. coli Biosensor Xiaofei Qin 1,2, Celina Vila-Sanjurjo 2,3, Ratna Singh 4, Bodo Philipp 5 and Francisco M. Goycoolea 2,6,* 1 Department of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai 519041, China; [email protected] 2 Laboratory of Nanobiotechnology, Institute of Plant Biology and Biotechnology, University of Münster, Schlossplatz 8, D-48143 Münster, Germany; [email protected] 3 Department of Pharmacology, Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, Campus Vida, s/n, 15782 Santiago de Compostela, Spain 4 Laboratory of Molecular Phytopathology and Renewable Resources, Institute of Plant Biology and Biotechnology, University of Münster, Schlossplatz 8, D-48143 Münster, Germany; [email protected] 5 Institute of Molecular Microbiology and Biotechnology, University of Münster, Corrensstraße 3, D-48149 Münster, Germany; [email protected] 6 School of Food Science and Nutrition, University of Leeds, Leeds LS2 9JT, UK * Correspondence: [email protected]; Tel.: +44-1133-431412 Received: 13 August 2020; Accepted: 18 September 2020; Published: 22 September 2020 Abstract: A library of 23 pure compounds of varying structural and chemical characteristics was screened for their quorum sensing (QS) inhibition activity using a synthetic fluorescent Escherichia coli biosensor that incorporates a modified version of lux regulon of Vibrio fischeri. Four such compounds exhibited QS inhibition activity without compromising bacterial growth, namely, phenazine carboxylic acid (PCA), 2-heptyl-3-hydroxy-4-quinolone (PQS), 1H-2-methyl-4-quinolone (MOQ) and genipin. When applied at 50 µM, these compounds reduced the QS response of the biosensor to 33.7% 2.6%, ± 43.1% 2.7%, 62.2% 6.3% and 43.3% 1.2%, respectively.
    [Show full text]
  • A Dissertation Entitled Uncovering Cannabinoid Signaling in C. Elegans
    A Dissertation Entitled Uncovering Cannabinoid Signaling in C. elegans: A New Platform to Study the Effects of Medicinal Cannabis By Mitchell Duane Oakes Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Doctor of Philosophy Degree in Biology ________________________________________ Dr. Richard Komuniecki, Committee Chair _______________________________________ Dr. Bruce Bamber, Committee Member ________________________________________ Dr. Patricia Komuniecki, Committee Member ________________________________________ Dr. Robert Steven, Committee Member ________________________________________ Dr. Ajith Karunarathne, Committee Member ________________________________________ Dr. Jianyang Du, Committee Member ________________________________________ Dr. Amanda Bryant-Friedrich, Dean College of Graduate Studies The University of Toledo August 2018 Copyright 2018, Mitchell Duane Oakes This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of Uncovering Cannabinoid Signaling in C. elegans: A New Platform to Study the Effects of Medical Cannabis By Mitchell Duane Oakes Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Doctor of Philosophy Degree in Biology The University of Toledo August 2018 Cannabis or marijuana, a popular recreational drug, alters sensory perception and exerts a range of medicinal benefits. The present study demonstrates that C. elegans exposed to
    [Show full text]
  • The Phytochemistry of Cherokee Aromatic Medicinal Plants
    medicines Review The Phytochemistry of Cherokee Aromatic Medicinal Plants William N. Setzer 1,2 1 Department of Chemistry, University of Alabama in Huntsville, Huntsville, AL 35899, USA; [email protected]; Tel.: +1-256-824-6519 2 Aromatic Plant Research Center, 230 N 1200 E, Suite 102, Lehi, UT 84043, USA Received: 25 October 2018; Accepted: 8 November 2018; Published: 12 November 2018 Abstract: Background: Native Americans have had a rich ethnobotanical heritage for treating diseases, ailments, and injuries. Cherokee traditional medicine has provided numerous aromatic and medicinal plants that not only were used by the Cherokee people, but were also adopted for use by European settlers in North America. Methods: The aim of this review was to examine the Cherokee ethnobotanical literature and the published phytochemical investigations on Cherokee medicinal plants and to correlate phytochemical constituents with traditional uses and biological activities. Results: Several Cherokee medicinal plants are still in use today as herbal medicines, including, for example, yarrow (Achillea millefolium), black cohosh (Cimicifuga racemosa), American ginseng (Panax quinquefolius), and blue skullcap (Scutellaria lateriflora). This review presents a summary of the traditional uses, phytochemical constituents, and biological activities of Cherokee aromatic and medicinal plants. Conclusions: The list is not complete, however, as there is still much work needed in phytochemical investigation and pharmacological evaluation of many traditional herbal medicines. Keywords: Cherokee; Native American; traditional herbal medicine; chemical constituents; pharmacology 1. Introduction Natural products have been an important source of medicinal agents throughout history and modern medicine continues to rely on traditional knowledge for treatment of human maladies [1]. Traditional medicines such as Traditional Chinese Medicine [2], Ayurvedic [3], and medicinal plants from Latin America [4] have proven to be rich resources of biologically active compounds and potential new drugs.
    [Show full text]
  • Microgram Journal, Vol 2, Number 1
    Washington, D. C. Office of Science and Education Vol.II,No.1 Division of Laboratory Operations January 1969 INDEXISSUE CORRECTION 11 "Structure Elucidation of 'LBJ' , by Sander W. Bellman, John W. Turczan, James Heagy and Ted M. Hopes, Micro­ Gram .!., 3, 6-13 (Dec. 1968) Page 7, third and fourth sentences under Discussion: Change to read: "The melting point of the acid moiety found in step (g) was 148-150°c., compared to the litera­ ture, v~lue of 151°c for the melting point of benzilic acid (2); thus the benzilic acid melting point gives support to the proposed structure for 'LBJ'. Spectral evidence also supports the proposed structure". MICRO-GRAMREVISION Please re-number the pages of your copies of Micro-Gram, Volume I. Re-number pages bearing printing only. Vol­ ume I will then be numbered from page 1, the front page of issue No. 1, through page 189 the last page of issue No. 12. To help with this task, pages contained within each issue are as follows: Issue Number Page Through 1 1 8 2 9 29 3 30 32 4 33 66 5 67 79 6 80 97 7 98 120 8 121 128 9 129 136 10 137 157 11 158 170 12 171 189 CAUTION: Use of this publication should be restricted to forensic analysts or others having a legitimate need for this material. From the Archive Library of Erowid Center http://erowid.org/library/periodicals/microgram -2- CANNABIS ,·,-...__/' Attached is a copy of 11A Short Rapid Method for the Identification of Cannabis." The method was developed by Mro H.D.
    [Show full text]
  • Tuning Drug Release from Polyoxazoline-Drug Conjugates T ⁎ J
    European Polymer Journal 120 (2019) 109241 Contents lists available at ScienceDirect European Polymer Journal journal homepage: www.elsevier.com/locate/europolj Tuning drug release from polyoxazoline-drug conjugates T ⁎ J. Milton Harrisa, ,1, Michael D. Bentleya, Randall W. Moreaditha, Tacey X. Viegasa,1, Zhihao Fanga, Kunsang Yoona, Rebecca Weimera, Bekir Dizmanb, Lars Nordstiernac a Serina Therapeutics, Inc., 601 Genome Way, Suite 2001, Huntsville, AL 35806, USA2 b Sabanci University, Faculty of Engineering and Natural Sciences, Tuzla, 34956 İstanbul, Turkey2 c Department of Chemistry and Chemical Engineering, Chalmers University of Technology, SE-412 96 Göteborg, Sweden ARTICLE INFO ABSTRACT Keywords: Poly(2-oxazoline)-drug conjugates with drugs attached via releasable linkages are being developed for drug Poly(2-oxazoline) or POZ delivery. Such conjugates with pendent ester linkages that covalently bind drugs to the polymer backbone ex- Poly(2-ethyl-2-oxazoline) or PEOZ hibit significantly slower hydrolytic release rates in plasma than the corresponding PEG- and dextran-drug Pendent drugs conjugates. The slow drug release rates in-vitro of these POZ-drug conjugates contribute to extended in-vivo Degradable ester linkages pharmacokinetic profiles. In some instances, the release kinetics may be relatively sustained and ideal foronce-a- Pharmacokinetics week subcutaneous injection, whereas the native drug by itself may only have an in-vivo half-life of a few hours. Drug delivery Phenolic drugs The origin of this unusual kinetic and pharmacokinetic behavior is proposed here to involve folding of the POZ conjugate such that the relatively hydrophobic drug forms a central core, and the relatively hydrophilic polymer wraps around the core and slows enzymatic attack on the drug-polymer chemical linkage.
    [Show full text]
  • Note: the Letters 'F' and 'T' Following the Locators Refers to Figures and Tables
    Index Note: The letters ‘f’ and ‘t’ following the locators refers to figures and tables cited in the text. A Acyl-lipid desaturas, 455 AA, see Arachidonic acid (AA) Adenophostin A, 71, 72t aa, see Amino acid (aa) Adenosine 5-diphosphoribose, 65, 789 AACOCF3, see Arachidonyl trifluoromethyl Adlea, 651 ketone (AACOCF3) ADP, 4t, 10, 155, 597, 598f, 599, 602, 669, α1A-adrenoceptor antagonist prazosin, 711t, 814–815, 890 553 ADPKD, see Autosomal dominant polycystic aa 723–928 fragment, 19 kidney disease (ADPKD) aa 839–873 fragment, 17, 19 ADPKD-causing mutations Aβ, see Amyloid β-peptide (Aβ) PKD1 ABC protein, see ATP-binding cassette protein L4224P, 17 (ABC transporter) R4227X, 17 Abeele, F. V., 715 TRPP2 Abbott Laboratories, 645 E837X, 17 ACA, see N-(p-amylcinnamoyl)anthranilic R742X, 17 acid (ACA) R807X, 17 Acetaldehyde, 68t, 69 R872X, 17 Acetic acid-induced nociceptive response, ADPR, see ADP-ribose (ADPR) 50 ADP-ribose (ADPR), 99, 112–113, 113f, Acetylcholine-secreting sympathetic neuron, 380–382, 464, 534–536, 535f, 179 537f, 538, 711t, 712–713, Acetylsalicylic acid, 49t, 55 717, 770, 784, 789, 816–820, Acrolein, 67t, 69, 867, 971–972 885 Acrosome reaction, 125, 130, 301, 325, β-Adrenergic agonists, 740 578, 881–882, 885, 888–889, α2 Adrenoreceptor, 49t, 55, 188 891–895 Adult polycystic kidney disease (ADPKD), Actinopterigy, 223 1023 Activation gate, 485–486 Aframomum daniellii (aframodial), 46t, 52 Leu681, amino acid residue, 485–486 Aframomum melegueta (Melegueta pepper), Tyr671, ion pathway, 486 45t, 51, 70 Acute myeloid leukaemia and myelodysplastic Agelenopsis aperta (American funnel web syndrome (AML/MDS), 949 spider), 48t, 54 Acylated phloroglucinol hyperforin, 71 Agonist-dependent vasorelaxation, 378 Acylation, 96 Ahern, G.
    [Show full text]
  • Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back
    International Journal of Molecular Sciences Review Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back Osnat Almogi-Hazan * and Reuven Or Laboratory of Immunotherapy and Bone Marrow Transplantation, Hadassah Medical Center, The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel; [email protected] * Correspondence: [email protected] Received: 21 May 2020; Accepted: 19 June 2020; Published: 23 June 2020 Abstract: The Cannabis plant contains numerous components, including cannabinoids and other active molecules. The phyto-cannabinoid activity is mediated by the endocannabinoid system. Cannabinoids affect the nervous system and play significant roles in the regulation of the immune system. While Cannabis is not yet registered as a drug, the potential of cannabinoid-based medicines for the treatment of various conditions has led many countries to authorize their clinical use. However, the data from basic and medical research dedicated to medical Cannabis is currently limited. A variety of pathological conditions involve dysregulation of the immune system. For example, in cancer, immune surveillance and cancer immuno-editing result in immune tolerance. On the other hand, in autoimmune diseases increased immune activity causes tissue damage. Immuno-modulating therapies can regulate the immune system and therefore the immune-regulatory properties of cannabinoids, suggest their use in the therapy of immune related disorders. In this contemporary review, we discuss the roles of the endocannabinoid system in immunity and explore the emerging data about the effects of cannabinoids on the immune response in different pathologies. In addition, we discuss the complexities of using cannabinoid-based treatments in each of these conditions.
    [Show full text]